Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients

Document Type: Short communication

Authors

1 Department of Biology, Arsanjan branch, Islamic Azad University, Arsanjan, Iran

2 Yong researchers and elite club, Islamic Azad University, Arsanjan Branch, Arsanjan, Iran

3 Shiraz Nephro-Urology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Endocrinology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Type 2 diabetes mellitus is a worldwide epidemic disorder with considerable health and economic consequences. Metformin is one of the most commonly prescribed oral antidiabetic drugs. Pharmacogenetic studies showed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to evaluate pharmacogenetic variation in SLC47A1 (rs2289669) and metformin response in type 2 diabetes patients. Seventy one patients with type 2 diabetes were included in the study. The genotypes were determined by Tetra–ARMS–PCR method. There was a significant association between the study polymorphism and the response to metformin treatment with the highest HbA1C reduction in AG genotype. In the dominant model for A allele (AA+AG vs GG), patients with A allele had highest HbA1C reduction in response to metformin.

Keywords


1. Cheung CY, Tso AW, Cheung BM, Xu A, Fong CH, Ong KL, Law LS, Wat NM, Janus ED, Sham PC, Lam KS. The KCNJ11 E23K polymorphism and progression of glycaemia in Southern Chinese: a long-term prospective study. PLoS One 2011; 6:e28598.

2. Semiz S, Dujic T, Causevic A. Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) 2013;23:154-171.

3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.

4. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012;35:446-445.

5. Graham GG1, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98.

6. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007;74:359-371.

7. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009;58:745-749.

8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29(Suppl. 1):S43-48.

9. Tkáč I, Klimčáková L, Javorský M, Fabianová M, Schroner Z, Hermanová H, Babjaková E, Tkáčová R. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 2013;15:189-191.

10. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP. Glycaemic durability of rosiglitazone, metformin, or glyburide monotherapy. New Engl J Med 2006;355:2427-2443.

11. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001;29:E88-8.

12. He R, Zhang D, Lu W, Zheng T, Wan L, Liu F, Jia W. SLC47A1 gene rs2289669 G.A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Diabetes Res Clin Pract 2015;109:57-63.